The Economist Intelligence Unit (EIU) found that new innovations in drug development positively impact drug development and market access, although the innovations are not yet widely adopted.

The EIU report, which was commissioned by Parexel, a clinical research organization, found that the new innovations showed a “surprisingly low” rate of adoption but positively affected drug success factors like clinical trial timelines, the probability of market launch and inclusion on selected payer formularies.

After assessing clinical trial data and other sources in the U.S., E.U., China and Japan, the report discovered that likelihood of launch was 10 percent higher for drugs developed with precision medicine trials, 13 percent higher for adaptive trials, 19 percent higher for patient-centric trials and 21 percent higher for trials that used real-world data.